L42-48 Flashcards

1
Q

Describe the typical cognitive decline associated with healthy aging including the effect of aging on mental speed, episodic memory, semantic memory and procedural memory.

A

Typical cognitive declines:
Processing speed, attention (complex tasks, not simple tasks), memory (mixed), visuospatial (complex tasks, not simple) and executive functions (mixed)

  • mental speed: declines with age (peaks around 30 yo)
  • episodic memory: declines (stable untill 50-60 yo)
  • semantic memory: no large impact
  • procedural memory: no large impact (some inconsistent findings, however)
  • free recall: declines (cued and recognition remains stable)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe the role of cognitive reserve in aging and neurodegeneration.

A

An AD patient with higher cognitive reserve will have a later onset of neuropathology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the typical memory impairments found in early neurodegenerative diseases as Alzheimer’s disease.

A

Most prominent symptoms of AD:
- impaired episodic memory, especially encoding of verbal info

Other deficits of mild/very mild degree
- executive functions
- attention and psychomotor speed
- language test
- visuospatial functions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Explain the term “dementia”.

A
  • symptom, not a disease
  • evidence of significant cognitive decline
  • the cognitive deficits interferewith independence in everyday activities
  • do not occur exclusively in the contex of delirium
  • are not better explained by other mental disorders
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Name some common neurodegenerative dementia disorders.

A

AD, Lewy body- and frontotemporal dementia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the most important risk factors for Alzheimer’s disease.

A

Age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the pathophysiology of Alzheimer’s disease with special emphasis on protein accumulation and its localization.

A

Plaques:
- amyloid beta plaques
- high expression of amyloid precursor protein (related to synaptic plasticity) in active brain areas
- in sporadic AD: clearance and not production is causing accumulation
- evidence suggests that intermediate stages of fibrillation are most toxic

Tangles:
- Tau neurofibrillary tangles
- Tau stabilizes microtubules, (phoshorylate and dephosphorylate to allow change)
- when hyperphosphorylated microtubules destabilize
- when a neuron degenerate, tau is released

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe typical symptoms of Alzheimer’s disease when the temporal lobe is affected.

A
  • episodic memory deficits: forgetting appointments, what you just talked about, recent events
  • semantic memory causing aphasia: difficulties in the ability to match words or images to their meanings
  • language: usually problems with nouns, uses other words, difficulty in understanding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Explain the association between pathophysiology and symptom development in Alzheimer’s disease.

A

Pathology often precedes clinical symptoms by decades:
- amyloid accumulation precedes neurogeneration, which precedes symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the use of different biomarkers diagnose Alzheimer’s disease.

A

Positive biomarkers (normal biomarkers in elderly with normal cognition): they will get AD if they live long enough? Risk factor, not disease marker?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe treatments for Alzheimer’s disease: symptomatic.

A
  • reduces symptoms with stability over a 1 year, then continued progression
  • cholinesterase inhibitors and NMDA antagonists - targeted at improving synaptic transmission
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Explain the term “dementia disorders”.

A

Disorders with dementia as a core symptom. Neuropathology are localized differently in different dementia disorders. Mixed pathology are very common.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the primary symptomatology of frontotemporal dementia: behavior.

A
  • disinhibition with inappropriate or socially unacceptable behavior
  • emotionally blunted
  • lack of empathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the primary symptomatology of Lewy body dementia.

A
  • progressive dementia
  • deficits in attention and executive functions
  • fluctating cognition
  • recurrent complex visual hallucinations
  • spontaneous features of parkinsonism
  • REM sleep disorder
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Explain the difference in amyloid-beta pathology in familial vs sporadic AD.

A

Familial: increased production
Sporadic: decreased clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the typical course of disease of Alzheimer’s disease.

A

Mean survival: 7 y

17
Q

Describe typical symptoms of Alzheimer’s disease when the parietal lobe is affected.

A
  • problems with finding the way, find or locate items in space, problems with reading, calculation
18
Q

Describe typical symptoms of Alzheimer’s disease when the frontal lobe is affected.

A
  • problems with performing or solving complex tasks, keeping overview of tasks, change in behavior and personality
19
Q

Describe the primary symptomatology of frontotemporal dementia: cognition.

A
  • lack of planning/organizing skills
  • reduced abstract thinking
  • reduced judgement
20
Q

Describe the primary symptomatology of frontotemporal dementia: language

A
  • progressive nonfluent aphasi: breakdown in speech, effortfull, hesitant (similar to stroke)
  • due to semantic memory deficits: increasing difficulty naming and word comprehension, loss of knowledge of words, objects and concepts
21
Q

Describe treatments for Alzheimer’s disease: potential disease-modifying new treatments.

A
  • reduces pathology (and symptoms) with a slower progression of the disease
  • monoclonal antibodies against A-beta
  • promising, but only 1 % of MABs cross the BBB
  • aducanumab approved by FDA to remove A-beta in 2021
  • new therapy: tau aggregation inhibitor